The mission of the Comprehensive Cancer Center at St. Jude Children's Research Hospital (SJCCC) is to advance cures and means of prevention for pediatric cancer: the leading cause of disease-related death in children aged 1 to 14 years. For 36 of our 50 year history, we have pursued this mission with the support of a Cancer Center Support Grant from the National Cancer Institute (NCI). We remain the only NCI designated Cancer Center that is dedicated solely to the research and treatment of pediatric malignancies. As such, we serve as a national and international resource for health care providers, children with cancer, and their families. Through the support of the American Lebanese and Syrian Associated Charities (ALSAC), a separate corporation whose sole purpose is to raise money in support of St. Jude Children's Research Hospital (SJCRH), patients are accepted without regard to race, religion or ability to pay. Seventy-five percent of the total institutional space and annual budget are invested in the SJCCC. The current application proposes five multidisciplinary research Programs that are organized with the specific intent of translating basic science discoveries into curative therapies for children with cancer, while minimizing long-term side effects: our three disease-oriented Programs focus on Developmental Biology and Solid Tumors (DBSTP), Hematological Malignancies (HMP), and Neurobiology and Brain Tumors (NBTP); our Cancer Prevention and Control Program (CPCP) strives to improve the quality of life of individuals surviving childhood cancer; and our new Cancer Genetics, Biochemistry and Cell Biology Program (CGBCBP), formed by merging our two prior basic laboratory research Programs, embeds basic cancer research within the heart of the SJCCC, facilitating direct interaction between the disease-oriented Programs and the major laboratory resources in the Center. Research by the 144 aligned members is supported by 10 Shared Resources and an outstanding clinical research infrastructure. During the previous funding period, a new Director was appointed and several enhancements were made to the overall structure, policies, and procedures of the SJCCC. 32,522 clinical trial enrollments occurred at the Center during the current funding period, of which 56% were to SJCCC investigator initiated studies. External peer reviewed trials, many which are SJCCC member-led, accounted for another 38% of enrollments. SJCCC members published more than 2,100 manuscripts during the funding period, and in the last 12 months were supported by $69.4 million in extramural funding ($57 million, peer-reviewed; $12.4 million, non-peer-reviewed).

Public Health Relevance

The five multidisciplinary research Programs and ten Shared Resources in the SJCCC work together to find cures for pediatric cancer, while minimizing the long-term side effects of treatment. With strong institutional and philanthropic support, for 50 years we have served as a national and international resource for health care providers, children with cancer, and their families. In this mission we accept patients without regard to race, religion or ability to pay.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA021765-38
Application #
9228935
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Program Officer
Marino, Michael A
Project Start
1997-04-01
Project End
2019-02-28
Budget Start
2017-03-01
Budget End
2018-02-28
Support Year
38
Fiscal Year
2017
Total Cost
$5,456,944
Indirect Cost
$2,416,864
Name
St. Jude Children's Research Hospital
Department
Type
Independent Hospitals
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Zheng, Daniel J; Krull, Kevin R; Chen, Yan et al. (2018) Long-term psychological and educational outcomes for survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study. Cancer 124:3220-3230
Fatima, Soghra; Zhou, Sheng; Sorrentino, Brian P (2018) Marking of definitive HSC precursors in E7.5-E8.5 embryos using an Abcg2-CreER lineage-tracing mouse model. Exp Hematol 65:29-33
Chen, Wenan; Li, Yan; Easton, John et al. (2018) UMI-count modeling and differential expression analysis for single-cell RNA sequencing. Genome Biol 19:70
Snaman, J M; Talleur, A C; Lu, J et al. (2018) Treatment intensity and symptom burden in hospitalized adolescent and young adult hematopoietic cell transplant recipients at the end of life. Bone Marrow Transplant 53:84-90
Robinson, Giles W; Rudneva, Vasilisa A; Buchhalter, Ivo et al. (2018) Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. Lancet Oncol 19:768-784
Creutzig, Ursula; Kutny, Matthew A; Barr, Ronald et al. (2018) Acute myelogenous leukemia in adolescents and young adults. Pediatr Blood Cancer 65:e27089
Gilleland Marchak, Jordan; Seidel, Kristy D; Mertens, Ann C et al. (2018) Perceptions of risk of infertility among male survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Cancer 124:2447-2455
Inaba, Hiroto; Cao, Xueyuan; Han, Alice Q et al. (2018) Bone mineral density in children with acute lymphoblastic leukemia. Cancer 124:1025-1035
Wilson, Carmen L; Howell, Carrie R; Partin, Robyn E et al. (2018) Influence of fitness on health status among survivors of acute lymphoblastic leukemia. Pediatr Blood Cancer 65:e27286
Mueller, Emily L; Park, Elyse R; Kirchhoff, Anne C et al. (2018) Insurance, chronic health conditions, and utilization of primary and specialty outpatient services: a Childhood Cancer Survivor Study report. J Cancer Surviv 12:639-646

Showing the most recent 10 out of 6764 publications